search
Back to results

Trial of Enteral Nutrition Enriched With Eicosapentaenoic Acid (EPA) in Upper Gastrointestinal Cancer Surgery

Primary Purpose

Esophageal Cancer

Status
Unknown status
Phase
Phase 4
Locations
Ireland
Study Type
Interventional
Intervention
Prosure
Ensure Plus
Sponsored by
University of Dublin, Trinity College
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Esophageal Cancer focused on measuring Esophageal Cancer, esophagectomy, enteral feeding, body composition, immunology

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult (male & female) patients >18 years with resectable esophageal cancer

Exclusion Criteria:

  • Patients with metastatic disease,
  • Non-operable cases,
  • Patients requiring chemotherapy/radiotherapy early following surgery,
  • Patients with known immunological disorder,
  • Emergency esophagectomy cases,
  • Patients with cardiac, liver or renal failure,
  • Active small intestinal disease eg Crohns disease,
  • Allergy to any of the ingredients,
  • Uncontrollable Diabetes,
  • Use of medications known to affect eicosanoid metabolism in two weeks prior to trial,
  • Use of fish oil/n-3 fatty acids,
  • Drug Abuse,
  • Unable to take preparation for 5 days preoperatively,
  • Pregnant women,
  • Cessation of enteral feeding for longer than 3 consecutive days post operatively for medical/surgical reasons (e.g. Chyle leaks).

Sites / Locations

  • St. James's Hospital,Recruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Immunonutrition Prosure

Standard enteral nutrition Ensure Plus

Arm Description

This group of patients are to be given a tube feed enriched with 2.2 g Eicosapentaenoic Acid (EPA) per day for 5 days pre surgery and 21 days post surgery

This group are to be given a standard enteral tube feed without EPA for 5 days pre op and 21 days post surgery

Outcomes

Primary Outcome Measures

Preservation of body compostition after surgery

Secondary Outcome Measures

Reduced immuno-inflammatory response to surgery

Full Information

First Posted
November 12, 2008
Last Updated
November 12, 2008
Sponsor
University of Dublin, Trinity College
Collaborators
Abbott
search

1. Study Identification

Unique Protocol Identification Number
NCT00790140
Brief Title
Trial of Enteral Nutrition Enriched With Eicosapentaenoic Acid (EPA) in Upper Gastrointestinal Cancer Surgery
Official Title
Randomized Double Blinded Trial to Investigate Effects of an Enteral Nutritional Supplement Enriched With Eicosapentaenoic Acid on Body Composition,Complications,Stress Response,Immune Function & Quality of Life in After Esophagectomy
Study Type
Interventional

2. Study Status

Record Verification Date
November 2008
Overall Recruitment Status
Unknown status
Study Start Date
July 2005 (undefined)
Primary Completion Date
July 2010 (Anticipated)
Study Completion Date
July 2010 (Anticipated)

3. Sponsor/Collaborators

Name of the Sponsor
University of Dublin, Trinity College
Collaborators
Abbott

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study aims to examine whether providing tube feeding with a formula enriched with omega-3 fats is better than traditional standard tube feeding in terms of preserving nutritional status, improving immune function and reducing medical complications following major upper Gut cancer surgery.
Detailed Description
Title A double blinded randomized controlled trial to investigate the effects of an enteral nutritional supplement enriched with Eicosapentaenoic acid on long term nutritional status post operatively specifically the maintenance of lean body mass, and its potential impact on quality of life as well as examining the stress response and immune function and in patients undergoing surgical treatment of esophageal cancer. Investigational medicinal Product(s): Prosure (Abbott Laboratories) Comparator: Ensure Plus (Abbott Laboratories) Study Objectives To examine whether prolonged supplementation with a nutritional supplement enriched with Eicosapentaenoic acid is superior to standard nutritional products in terms of promoting anabolism and improving quality of life in patients undergoing surgical treatment of esophageal cancer. Study Design - Prospective randomized controlled trial. Primary Endpoints: Quality of life Scores using EORTC Questionnaires Nutritional status on day 21 post oesophagectomy and/or total gastrectomy(specifically lean body mass) and at out patient follow up Secondary Endpoints: Effects on the immuno-inflammatory response to surgery Post operative Clinical outcome including SIRS, sepsis and organ failure

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Esophageal Cancer
Keywords
Esophageal Cancer, esophagectomy, enteral feeding, body composition, immunology

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Immunonutrition Prosure
Arm Type
Active Comparator
Arm Description
This group of patients are to be given a tube feed enriched with 2.2 g Eicosapentaenoic Acid (EPA) per day for 5 days pre surgery and 21 days post surgery
Arm Title
Standard enteral nutrition Ensure Plus
Arm Type
Placebo Comparator
Arm Description
This group are to be given a standard enteral tube feed without EPA for 5 days pre op and 21 days post surgery
Intervention Type
Dietary Supplement
Intervention Name(s)
Prosure
Other Intervention Name(s)
Prosure (Abbott Laboratories)
Intervention Description
This is an enteral tube feed with 125 kcals & 6.65g protein per 100mls. It contains Fat, Carbohydrate, and vitamins and minerals and is enriched with 2.2g Eicosapentaenoic Acid per 500mls of feed. Patients on this trial who are randomized to Prosure will receive the product orally for 5 days prior to surgery and for 21 days post surgery vis a feeding jejunostomy tube
Intervention Type
Dietary Supplement
Intervention Name(s)
Ensure Plus
Other Intervention Name(s)
Ensure Plus (Abbott Laboratories)
Intervention Description
This is a standard enteral tube feed with 150 kcals & 6.3 g protein per 100mls as well as carbohydrate, fat and vitamins and minerals. It does not have any active immunonutrients. Patients randomized to this arm will receive the product for 5 days pre op and 21 days post surgery via a feeding jejunostomy tube
Primary Outcome Measure Information:
Title
Preservation of body compostition after surgery
Time Frame
2 months
Secondary Outcome Measure Information:
Title
Reduced immuno-inflammatory response to surgery
Time Frame
2 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult (male & female) patients >18 years with resectable esophageal cancer Exclusion Criteria: Patients with metastatic disease, Non-operable cases, Patients requiring chemotherapy/radiotherapy early following surgery, Patients with known immunological disorder, Emergency esophagectomy cases, Patients with cardiac, liver or renal failure, Active small intestinal disease eg Crohns disease, Allergy to any of the ingredients, Uncontrollable Diabetes, Use of medications known to affect eicosanoid metabolism in two weeks prior to trial, Use of fish oil/n-3 fatty acids, Drug Abuse, Unable to take preparation for 5 days preoperatively, Pregnant women, Cessation of enteral feeding for longer than 3 consecutive days post operatively for medical/surgical reasons (e.g. Chyle leaks).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Aoife Ryan, PhD
Phone
+35314284452
Email
ryana1@tcd.ie
First Name & Middle Initial & Last Name or Official Title & Degree
John V Reynolds, MD
Phone
+35314162211
Email
reynoldsjv@stjames.ie
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Laura A Healy, BSc RD
Organizational Affiliation
St. James's Hospital, Dublin 8, Ireland
Official's Role
Principal Investigator
Facility Information:
Facility Name
St. James's Hospital,
City
Dublin
ZIP/Postal Code
8
Country
Ireland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Aoife Ryan, PhD
Phone
+35314284452
Email
ryana1@tcd.ie
First Name & Middle Initial & Last Name & Degree
Laura A Healy
Phone
+35314284452
Email
lhealy@stjames.ie
First Name & Middle Initial & Last Name & Degree
John V Reynolds, MD

12. IPD Sharing Statement

Citations:
PubMed Identifier
28742713
Citation
Healy LA, Ryan A, Doyle SL, Ni Bhuachalla EB, Cushen S, Segurado R, Murphy T, Ravi N, Donohoe CL, Reynolds JV. Does Prolonged Enteral Feeding With Supplemental Omega-3 Fatty Acids Impact on Recovery Post-esophagectomy: Results of a Randomized Double-Blind Trial. Ann Surg. 2017 Nov;266(5):720-728. doi: 10.1097/SLA.0000000000002390.
Results Reference
derived
PubMed Identifier
19247018
Citation
Ryan AM, Reynolds JV, Healy L, Byrne M, Moore J, Brannelly N, McHugh A, McCormack D, Flood P. Enteral nutrition enriched with eicosapentaenoic acid (EPA) preserves lean body mass following esophageal cancer surgery: results of a double-blinded randomized controlled trial. Ann Surg. 2009 Mar;249(3):355-63. doi: 10.1097/SLA.0b013e31819a4789.
Results Reference
derived

Learn more about this trial

Trial of Enteral Nutrition Enriched With Eicosapentaenoic Acid (EPA) in Upper Gastrointestinal Cancer Surgery

We'll reach out to this number within 24 hrs